GRIN2B encodes the GluN2B (also called NR2B) subunit of the N-methyl-D-aspartate (NMDA) type of ionotropic glutamate receptor[@paoletti2013]. NMDA receptors are glutamate-gated, voltage-dependent calcium channels essential for synaptic transmission, synaptic plasticity, and activity-dependent gene expression. The GluN2B subunit confers distinctive physiological properties — including prolonged channel open time, high calcium permeability, and specific trafficking patterns — that are critical for hippocampal-dependent learning and memory, and whose dysregulation is implicated across Alzheimer's disease, Parkinson's disease, stroke, and neurodevelopmental disorders[@loftis2003].
The GluN2B subunit is encoded by GRIN2B on chromosome 12p13.1. During brain development, GluN2B is widely expressed, but its expression becomes progressively restricted to forebrain regions (particularly the hippocampus and cortex) in the adult brain, with expression declining further with age — a pattern with significant implications for age-related cognitive decline[@Cull-Candy2001].
| Attribute |
Value |
| Protein Name |
Glutamate Ionotropic Receptor NMDA Type Subunit 2B (GluN2B/NR2B) |
| Gene Symbol |
GRIN2B |
| UniProt ID |
Q8VHX6 (mouse, ortholog) |
| Human UniProt |
Q13224 |
| Molecular Weight |
~180 kDa (full-length); C-terminal tail ~70 kDa |
| Protein Length |
1,484 amino acids |
| Chromosomal Location |
12p13.1 |
| Subcellular Location |
Postsynaptic membrane, endoplasmic reticulum, Golgi |
| Protein Family |
Ionotropic glutamate receptor (iGluR) family |
¶ Domain Architecture
The GluN2B subunit adopts the canonical iGluR topology[@paoletti2013]:
Extracellular Domain (~570 residues):
- ATD (Amino-Terminal Domain): Controls subunit assembly, controls agonist potency, mediates allosteric modulation by ifenprodil and related compounds
- LBD (Ligand-Binding Domain): Bilobed structure binding glutamate (primary agonist) and glycine (co-agonist). The LBD undergoes domain closure upon agonist binding, driving channel opening
Transmembrane Domain:
- Four transmembrane helices (M1–M4)
- M2 forms the pore loop with a selectivity filter determining calcium permeability
- The re-entrant M2 loop determines single-channel conductance
C-Terminal Domain (~640 residues):
- Intracellular region bearing multiple serine, threonine, and tyrosine phosphorylation sites
- Contains PDZ-binding motif for interaction with PSD-95, SAP97, and other MAGUK proteins
- Critical for synaptic targeting, trafficking, and protein-protein interactions
- Heavily regulated by kinases (CaMKII, PKC, Src family) and phosphatases
¶ Assembly and Stoichiometry
Native NMDA receptors are obligate heteromers:
- Diheteromeric: 2 GluN1 + 2 GluN2 (any subtype)
- Triheteromeric: 2 GluN1 + 1 GluN2A + 1 GluN2B
- GluN1 is the essential subunit (GRIN1 gene); GluN2B cannot form functional channels alone
GluN2B-containing NMDA receptors mediate several critical processes[@laurence2008]:
- Calcium influx: High calcium permeability (PCa/PNa ~10) drives intracellular signaling cascades
- Synaptic plasticity: Mediates long-term potentiation (LTP) and long-term depression (LTD) in the hippocampus
- Synaptic tagging: Couples synaptic activity to gene transcription for memory consolidation
- Critical period plasticity: Enhanced during early postnatal development when environmental experience shapes neural circuits
Downstream of GluN2B activation:
- CaMKII activation: Autophosphorylation at T286, stabilizing synaptic potentiation
- CREB phosphorylation: Activity-dependent gene expression (Bdnf, Arc, c-fos)
- ERK/MAPK pathway: Synaptic protein synthesis and consolidation
- Calcineurin/NFAT signaling: Bidirectional synaptic modulation
¶ Regional and Temporal Expression
- Developmental: Ubiquitously expressed across the CNS during fetal and early postnatal development
- Adult: Enriched in hippocampus, cortex, striatum, and thalamus
- Age-related decline: GluN2B expression at synapses decreases with normal aging, contributing to cognitive decline
- Synaptic vs. extrasynaptic: Predominantly synaptic in mature neurons; extrasynaptic GluN2B-NMDARs trigger distinct (often pro-death) signaling
GluN2B dysregulation is a hallmark of early AD pathogenesis[@liu2007]:
Excitotoxicity and calcium dysregulation:
- Aβ oligomers activate GluN2B-containing NMDARs, causing pathological calcium influx
- Excessive calcium influx activates calpains, caspases, and other proteases
- Mitochondrial calcium overload leads to ROS generation and bioenergetic failure[@tu2014]
Synaptic damage:
- Aβ-induced overactivation of synaptic NMDARs triggers internalization of AMPARs and NMDARs
- Synaptic GluN2B loss precedes and predicts cognitive decline in animal models
- Disruption of CaMKII signaling at synapses impairs LTP
Extrasynaptic GluN2B:
- Aβ promotes translocation of GluN2B to extrasynaptic sites
- Extrasynaptic GluN2B-NMDARs activate distinct signaling (pro-death pathways including PDE4, PP1)
- Extrasynaptic NMDAR blockade is neuroprotective in AD models[@hardingham2007]
Therapeutic approaches:
- Memantine: Low-affinity, uncompetitive NMDAR antagonist approved for moderate AD; preferentially blocks extrasynaptic NMDARs at therapeutic concentrations
- NR2B-selective antagonists: Ifenprodil and analogs show promise in preclinical models
- Allosteric modulators: Negative allosteric modulators targeting the ifenprodil binding site
NMDARs — particularly GluN2B-containing receptors — play key roles in PD pathophysiology[@kalia2008]:
Dopaminergic pathway dysregulation:
- Loss of substantia nigra dopaminergic neurons disrupts striatal NMDAR regulation
- Striatal GluN2B expression is altered in PD models and patients
- Enhanced NMDAR signaling contributes to aberrant corticostriatal plasticity
L-DOPA-induced dyskinesia (LID):
- Chronic L-DOPA treatment produces excessive NMDAR activity in striatal neurons
- GluN2B upregulation is associated with LID severity
- NR2B-selective antagonists (e.g., ifenprodil) reduce dyskinesia in animal models without diminishing antiparkinsonian efficacy
Neuroprotection:
- NMDAR antagonists are neuroprotective in toxin-based PD models
- Memantine has been explored as an adjunct to dopaminergic therapy
¶ Stroke and Ischemia
Cerebral ischemia triggers massive glutamate release, leading to excitotoxic neuronal death[@kalia2008]:
Mechanism:
- Oxygen-glucose deprivation causes energy failure, removing the voltage-dependent Mg²⁺ block on NMDARs
- Excessive glutamate activates NMDARs including GluN2B-containing receptors
- Massive Ca²⁺ influx triggers necrotic and apoptotic cascades
Therapeutic challenge:
- Global NMDAR blockade is neuroprotective but causes unacceptable psychotomimetic side effects
- NR2B-selective antagonists are more promising — neuroprotective in ischemia models with better safety margins
- Timing is critical: NMDAR antagonists are most effective when administered before or shortly after ischemic insult
GRIN2B mutations cause a spectrum of neurodevelopmental conditions[@chang2022]:
| Condition |
Mutation Type |
Clinical Features |
| Intellectual disability |
Missense, nonsense |
Moderate-severe ID, absent speech, motor delay |
| Autism spectrum disorder |
Missense |
ASD with ID, seizures, ADHD |
| Schizophrenia |
Rare variants |
Early-onset psychosis, cognitive impairment |
| Epilepsy |
Missense |
Drug-resistant focal epilepsy |
Gain-of-function mutations (increased current, enhanced Ca²⁺ influx) cause severe early-onset encephalopathy with infantile spasms and developmental regression. Loss-of-function mutations produce intellectual disability with speech delay and dysmorphic features.
| Drug |
Mechanism |
Indication |
Notes |
| Memantine |
Low-affinity, uncompetitive NMDAR antagonist |
Moderate-severe AD |
Prefers extrasynaptic over synaptic NMDARs; FDA-approved |
| Amantadine |
NMDAR antagonist + dopamine release |
PD (LID reduction) |
Off-label; modest efficacy |
NR2B-selective antagonists:
- Ifenprodil and analogs (e.g., CP-101,606/Trax配) — demonstrated neuroprotection in stroke, PD, and AD models
- Challenge: selectivity is relative, not absolute — off-target effects on other targets
Allosteric modulators:
- Rapastinel-like agents: Positive allosteric modulators (PAMs) targeting synaptic GluN2B-NMDARs for cognition enhancement
- Negative allosteric modulators (NAMs) for excitotoxicity
Downstream targets:
- CaMKII modulators: Enhance synaptic plasticity without broad NMDAR blockade
- CREB enhancers: Bdnf-boosting strategies
- Memantine: Approved and widely used
- NR2B antagonists: Multiple trials in AD, PD, and stroke — mixed results; no approved NR2B-selective drug
- Prevention trials: Targeting early NMDAR dysfunction before neurodegeneration
flowchart TD
A["Glutamate Release"] --> B["Synaptic Vesicle Fusion"]
B --> C["GluN2B-NMDAR Activation<br/>(Requires depolarization to remove Mg2+ block)"]
C --> D["Ca2+ Influx"]
D --> E1["Synaptic NMDAR"]
D --> E2["Extrasynaptic NMDAR"]
E1 --> F["CaMKII Activation<br/>Synaptic strengthening"]
E1 --> G["CREB Phosphorylation<br/>Gene expression"]
E2 --> H["PP1/PDE4 Activation<br/>Pro-death signaling"]
H --> I["Bdnf downregulation<br/>Synaptic weakening"]
I --> J["Tau pathology<br/>Neuronal death"]
style A fill:#e1f5fe,stroke:#333
style F fill:#c8e6c9,stroke:#333
style J fill:#ffcdd2,stroke:#333
- GRIN1 — Essential partner subunit forming functional NMDARs
- GRIN2A — Alternate GluN2 subunit with distinct properties
- PSD-95 — Scaffolding protein linking GluN2B to downstream signaling
- CaMKII — Key downstream effector
- AMPAR — Synaptic co-receptor for rapid glutamatergic transmission
- Paoletti P, et al, NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease (2013)
- Loftis JM, et al, N-methyl-D-aspartate receptor subunit NR2B: molecular features and therapeutic implications (2003)
- Liu J, et al, Role of NMDA receptor subtypes in the pathogenesis of Alzheimer's disease (2007)
- Cull-Candy SG, et al, NMDA receptor subunits: diversity, development and disease (2001)
- Chen LJ, et al, NR2B transgenic mice: from enhanced cognition to neurodegeneration (2008)
- Kalia LV, et al, NMDA receptors in the pathophysiology and treatment of Parkinson's disease (2008)
- Lau CG, et al, Role of NMDA receptor trafficking in synaptic plasticity and disease (2009)
- Hardingham GE, et al, Extrasynaptic NMDARs oppose synaptic NMDARs by promoting cortical cell survival (2007)
- LaFerla FM, et al, Intracellular amyloid-beta in Alzheimer's disease (2007)
- Tu S, et al, Inflammatory neuronal death in Alzheimer's disease: Role of NMDA receptor overactivation (2014)
- Gardoni F, et al, Targeting NMDA receptor subunits as a strategy to treat Alzheimer's disease (2009)
- Chang CH, et al, GRIN2B variants in neurodevelopmental disorders: a systematic review (2022)